Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial

BACKGROUND: Serotonin is a mediator of pulmonary hypoxic vasoconstriction. Experimental studies have shown that serotonin-mediated pulmonary vasoconstriction can be inhibited by cyproheptadine. The aim of this study is to assess whether treatment with cyproheptadine compared to usual care increases...

Descripción completa

Detalles Bibliográficos
Autores principales: Boniatti, Márcio Manozzo, Nedel, Wagner Luis, Rihl, Marcos Frata, Schwarz, Patricia, Parolo, Edino, Moretti, Miriane Melo Silveira, Lisboa, Thiago Costa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2023
Materias:
Brief Research Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369312/
https://www.ncbi.nlm.nih.gov/pubmed/37502298
http://dx.doi.org/10.5005/jp-journals-10071-24482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369312/
https://www.ncbi.nlm.nih.gov/pubmed/37502298
http://dx.doi.org/10.5005/jp-journals-10071-24482

Ejemplares similares